From the Department of Pathology and Laboratory Medicine (C.X., B.C.B.), University of Rochester, NY.
Aab Cardiovascular Research Institute (C.X., S.S., M.S., J.P., J.W., B.C.B.), University of Rochester, NY.
Hypertension. 2020 Oct;76(4):1113-1123. doi: 10.1161/HYPERTENSIONAHA.119.14013. Epub 2020 Aug 24.
Oxidative stress and inflammation play key roles in development of pulmonary arterial hypertension (PAH). We previously reported that an endothelial cell (EC)-specific cyclophilin A overexpression mouse developed many characteristics of PAH. In other models of cardiovascular disease, cyclophilin A stimulates smooth muscle proliferation and vascular inflammation, but mechanisms responsible for PAH have not been defined. In particular, the contribution of endothelial-to-mesenchymal transition in cyclophilin A-mediated PAH has not been studied. We identified increased levels of cyclophilin A in endothelial and neointimal cells of pulmonary arteries in patients with PAH and animal pulmonary hypertension models. In the EC-specific cyclophilin A overexpression mouse that exhibited features characteristic of PAH, lineage tracing showed high level expression of mesenchymal markers in pulmonary ECs. A significant number of mesenchymal cells in media and perivascular regions of pulmonary arterioles and alveoli were derived from ECs. Pulmonary ECs isolated from these mice showed phenotypic changes characteristic of endothelial-to-mesenchymal transition in culture. Cultured pulmonary ECs stimulated with extracellular cyclophilin A and acetylated cyclophilin A demonstrated functional changes associated with endothelial-to-mesenchymal transition such as increased cytokine release, migration, proliferation, and mitochondrial dysfunction. Acetylated cyclophilin A stimulated greater increases for most features of endothelial-to-mesenchymal transition. In conclusion, extracellular cyclophilin A (especially acetylated form) contributes to PAH by mechanisms involving increased endothelial-to-mesenchymal transition, cytokine release, EC migration, proliferation, and mitochondrial dysfunction; strengthening the basis for studying cyclophilin A inhibition as a therapy for PAH.
氧化应激和炎症在肺动脉高压 (PAH) 的发展中起关键作用。我们之前报道过,内皮细胞 (EC) 特异性环孢素 A 过表达小鼠表现出许多 PAH 的特征。在其他心血管疾病模型中,环孢素 A 刺激平滑肌增殖和血管炎症,但尚未确定导致 PAH 的机制。特别是,内皮细胞向间充质转化在环孢素 A 介导的 PAH 中的作用尚未研究。我们在 PAH 患者和动物肺动脉高压模型的肺动脉内皮细胞和新生内膜细胞中发现环孢素 A 水平升高。在表现出 PAH 特征的 EC 特异性环孢素 A 过表达小鼠中,谱系追踪显示肺 EC 中间质标志物的高水平表达。肺小动脉和肺泡的中膜和血管周围区域的大量间质细胞来源于 EC。从这些小鼠中分离的肺 EC 在培养中表现出内皮细胞向间充质转化的表型变化。用细胞外环孢素 A 和乙酰化环孢素 A 刺激培养的肺 EC 可观察到与内皮细胞向间充质转化相关的功能变化,例如细胞因子释放、迁移、增殖和线粒体功能障碍。乙酰化环孢素 A 刺激大多数内皮细胞向间充质转化特征的增加更为显著。总之,细胞外环孢素 A(特别是乙酰化形式)通过增加内皮细胞向间充质转化、细胞因子释放、EC 迁移、增殖和线粒体功能障碍等机制导致 PAH;为研究环孢素 A 抑制作为 PAH 的治疗方法提供了更坚实的基础。